Phase I Study of Milatuzumab for Graft Versus Host Disease

Inclusion Criteria: * Males or non-pregnant, non-lactating females, ≥ 18 years of age * Able to understand and willing to sign informed consent. * Histologically confirmed hematologic malignancy that is deemed best treated by RIC allogeneic SCT, including: * Acute myeloid or lymphoblastic leukemia (AML, ALL) with \< 5% blasts in the bone marrow * Myelodysplastic syndrome and intermediate-2 or high-risk IPSS score with \< 5% blasts in the bone marrow * Chronic myelogenous leukemia failing to respond to at least two different tyrosine kinase inhibitors * Multiple myeloma that has relapsed following autologous stem cell transplant * Follicular lymphoma (grades 1, 2, or 3a by WHO criteria) or monocytoid lymphoma that has relapsed following at least two prior chemotherapy regimens and with either no lymph node groups ≥ 3 cm or with a ≥ 50% reduction in estimated lymph node diameter with most recent salvage therapy * Diffuse large B-cell NHL that has relapsed after at least 2 prior chemotherapy regimens (could include high-dose chemotherapy with autologous stem cell rescue) and is still sensitive to chemotherapy by virtue of a PR or CR following most recent salvage chemotherapy * Transformed follicular lymphoma that has achieved a PR or CR following chemotherapy * Mantle cell lymphoma that has relapsed after at least 2 prior chemotherapy regimens (could include high-dose chemotherapy with autologous stem cell rescue) * CLL/SLL/PLL that meets one of the following: * del (17p13.1) i…